Monitor upcoming FDA interactions and clinical trial progress for ozekibart, as positive developments could significantly impact the company's valuation.
Price Chart
Executive Summary
Inhibrx Biosciences announced positive interim data from its Phase 1/2 trial of ozekibart in late-line colorectal cancer, showing a 20% objective response rate and durable disease control in a heavily pretreated population. The company also plans to meet with the FDA to discuss accelerated approval pathways for colorectal cancer and Ewing sarcoma, and submitted a BLA for chondrosarcoma.
Key Facts
- Ozekibart demonstrated a 20% objective response rate in 45 evaluable patients with late-line colorectal cancer
- Median progression-free survival was 5.5 months, with 42% of patients progression-free at 6 months
- Disease control rate was 87% in the colorectal cancer cohort
- Company submitted a Biologics License Application (BLA) for ozekibart in chondrosarcoma
- Plans to meet with FDA to discuss accelerated approval pathways for colorectal cancer and Ewing sarcoma
Financial Impact
Potential for accelerated approval pathways and expanded indications could significantly increase the drug's commercial value
Risk Factors
- Interim data may not be representative of final results
- FDA may not grant accelerated approval pathways
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002007919-26-000010 |
| Exhibit: exhibit991-pressreleaseapr.htm | 0002007919-26-000010 |
| Document: inhibrxpresentation_apri.htm | 0002007919-26-000010 |
| Document: 0002007919-26-000010-index-headers.html | 0002007919-26-000010 |
| Document: 0002007919-26-000010-index.html | 0002007919-26-000010 |
| Document: 0002007919-26-000010.txt | 0002007919-26-000010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Buy | $90.50 | awaiting T+60 | — | $90.84 (+0.38%) |
Sep 28, 2026 27d ago | Insider Cluster | $104.83 | awaiting T+60 | — | $90.84 (−13.35%) |
Sep 17, 2026 5w ago | Insider Cluster | $109.35 | awaiting T+60 | — | $90.84 (−16.93%) |
Sep 15, 2026 5w ago | Insider Cluster | $101.77 | awaiting T+60 | — | $90.84 (−10.74%) |
Sep 15, 2026 5w ago | 144 | $101.77 | awaiting T+60 | — | $90.84 (−10.74%) |
Sep 14, 2026 5w ago | 144 | $105.61 | awaiting T+60 | — | $90.84 (−13.99%) |
Sep 11, 2026 6w ago | 144 | $109.27 | awaiting T+60 | — | $90.84 (−16.87%) |
Sep 10, 2026 6w ago | Insider Cluster | $109.27 | awaiting T+60 | — | $90.84 (−16.87%) |
Sep 8, 2026 6w ago | Insider Cluster | $112.86 | awaiting T+60 | — | $90.84 (−19.51%) |
Sep 8, 2026 6w ago | Insider Buy | $112.86 | awaiting T+60 | — | $90.84 (−19.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers